Tuberculosis or TB caused by the micro-organism Mycobacterium tuberculosis is a highly contagious and the second most fatal disease after AIDS. It is estimated that it will soon surpass the deaths caused by HIV.BCG is the only vaccine available to prevent TB, however it is not effective in case of adult pulmonary TB which is actually the most common type of TB. The currently used treatment regimen in most developing countries is a single tablet with fixed dose combination of four drugs- Isoniazid (INH), Rifampicin, Ethambutol and Pyrazinamide which are 1st line anti-tubercular drugs. This combination reduces the risk of development of multi-drug resistant (MDR) Mycobacterium. But this drug combination is known to have various severe side-effects, which if not taken into consideration might lead to fatal reactions. MDR-TB treatment involves the use of 2nd line drugs which are less potent and more toxic compared to 1st line drugs. Increasing number of MDR strains of mycobacterium and failure of these conventional regimens to treat them is a huge challenge. Also, these side-effects associated with anti-TB drugs are a major reason for patient non-compliance and non-adherence to the treatment. Treatment discontinuation leads to increased risk of mortality and morbidity due to TB. Thus, it is very important to develop new therapeutic approaches towards the treatment of this disease which provide a better cure without relapse, lesser side-effects and prevents formation of drug resistant strains. The article reviews the various side-effects associated with the Anti-Tubercular drugs that are currently used and discusses certain newer, nanoparticle-basedapproaches to overcome the shortcomings of the current conventional therapy.
Cite this article:
Harshada R Bandgar. Side Effects of TB Therapy and Recent Therapeutic Approaches for Tuberculosis Management. Asian Journal of Pharmaceutical Research. 2023; 13(1):31-3. doi: 10.52711/2231-5691.2023.00005
Harshada R Bandgar. Side Effects of TB Therapy and Recent Therapeutic Approaches for Tuberculosis Management. Asian Journal of Pharmaceutical Research. 2023; 13(1):31-3. doi: 10.52711/2231-5691.2023.00005 Available on: https://asianjpr.com/AbstractView.aspx?PID=2023-13-1-5
1. World Health Organization. Global tuberculosis report 2020. Geneva: World Health Organization, 2020.
2. Lalit Kumar, Rajan, Vivek Sharma. Tuberculosis: A Brief Overview. Asian J. Pharm. Res. 2(2): April-June 2012; Page 59-62
3. Uma Sankarviriti, Swarna LathaSurakala, Arun SatyadevSidhanadam, NeelimaPeela. Influence of HIV, Malnutrition and Patient Non-Compliance on the Prevalence and Prognosis of Tuberculosis: A Fatal Infectious Disease. Research J. Pharm. and Tech. 8(10): Oct., 2015; Page 1365-1368.
4. Durand F, Bernuau J, Pessayre D, Samuel D, Belaiche J, Degott C, Bismuth H, Belghiti J, Erlinger S, Rueff B, et al. Deleterious influence of pyrazinamide on the outcome of patients with fulminant or subfulminant liver failure during antituberculous treatment including isoniazid. Hepatology 1995;21:929–932
5. S. Ramachandran, VijeyAanandhi M, Binoy Varghese Cheriyan. Assessment of Antitubercular Activity- A Review. Research J. Pharm. and Tech 2019; 12(8):3973-3978. (mdr)
7. Sharma, S. K. ; Mohan, A. (2004) Multidrug-resistant tuberculosis Indian Journal of Medical Research, 120 (4). pp. 354-376. ISSN 0971-5916
8. Brennan, Patrick J. "Structure, function, and biogenesis of the cell wall of Mycobacterium tuberculosis." Tuberculosis 83.1-3 (2003): 91-97.
9. Huebner RE, Schein MF, Bass JB Jr. The tuberculin skin test. Clin Infect Dis 1993;17:968–975.
10. Wang L, Turner MO, Elwood RK, Schulzer M, FitzGerald JM. A meta-analysis of the effect of Bacille Calmette Guerin vaccination on tuberculin skin test measurements. Thorax 2002; 57: 804–809.
11. Lobue, Philip, and Dick Menzies. "Treatment of latent tuberculosis infection: an update." Respirology 15.4 (2010): 603-622.
12. SagavkarSandhyarani R, Devkar Swati R. Tuberculosis: A Review. Asian J. Pharm. Res. 2018; 8(3): 191-194.
13. Shi, Ruiru, NobunoriItagaki, and Isamu Sugawara. "Overview of anti-tuberculosis (TB) drugs and their resistance mechanisms." Mini reviews in medicinal chemistry 7.11 (2007): 1177-1185.
14. Dickinson JM, Aber VR, Mitchison DA. Bactericidal activity of streptomycin, isoniazid, rifampin, ethambutol, and pyrazinamide alone and in combination against Mycobacterium Tuberculosis. Am Rev Respir Dis. 1977 Oct; 116(4): 627–635.
15. Naing NN, D’Este C, Isa AR, Salleh R, Bakar N, Mahmod MR. Factors contributing to poor compliance with anti-TB treatment among tuberculosis patients. Southeast Asian J Trop Med Public Health. 2001;32(2):369–82.
16. Liam CK, Lim KH, Wong CM, Tang BG. Attitudes and knowledge of newly diagnosed tuberculosis patients regarding the disease, and factors affecting treatment compliance. Int J Tuberc Lung Dis. 1999;3(4):300–9.
17. Arbex, Marcos Abdo, et al. "Antituberculosis drugs: drug interactions, adverse effects, and use in special situations-part 1: first-line drugs." JornalBrasileiro de Pneumologia 36 (2010): 626-640.
18. Chung-Delgado, Kocfa, et al. "Factors associated with anti-tuberculosis medication adverse effects: a case-control study in Lima, Peru." PloS one 6.11 (2011): e27610.
19. Saranya, Parthasarathy V, Hariprasad B, Shobha Rani H. Factors Influencing Rifampicin Autoinduction in Adult Pulmonary Tuberculosis Patients. Research J. Pharm. and Tech 2016; 9(8):1223-1228.
20. Taramian, S., et al. "Side effects of first-line anti tuberculosis drugs." Journal of Guilan University of Medical Sciences 22.85 (2013): 42-47.
21. Deepalakshmi M, Anu Vikashini.R, Dinesh.R, JerlinAnusha.R, Dharini, Arun K.P. A rare case of Isoniazid-induced SJ syndrome in a secondary care hospital in rural South India - A Case Report. Research J. Pharm. and Tech 2020; 13(2):758-760.
22. Sandip Zine, Shweta A. Patankar, Sushmita S. Raopati. Rise of Antibiotic Resistance in Tuberculosis. Research J. Pharm. and Tech 2018; 11(7): 3201-3204.
23. Jaya Martolia, Hardik Soni, Falguni Tandel. Natural perspective for Management of drug resistant Tuberculosis: A Review. Research J. Pharm. and Tech. 2020; 13(8):4002-4008.
24. Monesh O. Patil, Yogesh S. Mali, Paresh A. Patil, D. R. Karnavat. Development of Immunotherapeutic Nanoparticles for treatment of Tuberculosis. Asian J. Pharm. Res. 2020; 10(3):226-232.
25. M. Xavier Suresh, J. A. Mahalakshmi, G.Vinisha. Computational Modeling of Novel Drug Targets ftsE and mpt83 for MDRTB and Molecular Docking of Selected Compounds from Medicinal Plants. Research J. Pharm. and Tech 2018; 11(4): 1413-1420.
26. Nasiruddin, Mohammad, Md Neyaz, and Shilpi Das. "Nanotechnology-based approach in tuberculosis treatment." Tuberculosis research and treatment 2017 (2017)
27. Banyal, Shelza, et al. "Advances in nanotechnology for diagnosis and treatment of tuberculosis." Current opinion in pulmonary medicine 19.3 (2013): 289-297.